Updated: January 15, 2026
Why Is Dexmethylphenidate/Serdexmethylphenidate (Azstarys) So Hard to Find? [Explained for 2026]
Author
Peter Daggett

Summarize with AI
- What Is Dexmethylphenidate/Serdexmethylphenidate (Azstarys)?
- Is There an Official Azstarys Shortage?
- 5 Reasons Azstarys Can Be Hard to Find in 2026
- 1. It's a Brand-Only Medication With Low Routine Stocking
- 2. The Broader ADHD Stimulant Demand Surge Is Still Ongoing
- 3. DEA Production Quotas Apply to Dexmethylphenidate
- 4. Insurance Restrictions Can Drive Patients to Brand-Only Options
- 5. Uneven Distribution Across Pharmacy Chains
- How Hard Is It to Find Azstarys Compared to Other ADHD Medications?
- What Can You Do to Find Azstarys Near You?
- Will Azstarys Get Easier to Find?
Azstarys (dexmethylphenidate/serdexmethylphenidate) can be hard to find in 2026. Here's why — and what you can do about it.
If you've been to multiple pharmacies looking for Azstarys — the brand name for dexmethylphenidate/serdexmethylphenidate — and come up empty-handed, you're not alone. Despite not being on the FDA's official drug shortage list, Azstarys can still be surprisingly difficult to find at your local pharmacy in 2026. Here's a plain-English explanation of why that is, and what you can realistically do about it.
What Is Dexmethylphenidate/Serdexmethylphenidate (Azstarys)?
Azstarys is a once-daily prescription stimulant approved by the FDA in March 2021 for the treatment of ADHD in patients aged 6 and older. It's a combination product made up of two ingredients:
Serdexmethylphenidate (SDX) — a novel prodrug (70% of the capsule) that is pharmacologically inactive until it's metabolized in the lower GI tract, where it slowly converts into dexmethylphenidate. This extended-release mechanism provides all-day ADHD symptom control.
Dexmethylphenidate (d-MPH) — an immediate-release stimulant (30% of the capsule) that kicks in within about 30 minutes to provide fast symptom onset at the start of the day.
Because serdexmethylphenidate is a brand-new chemical entity with no generic equivalent, Azstarys is only available as a brand-name medication. No generic is expected until at least 2037.
Is There an Official Azstarys Shortage?
As of early 2026, Azstarys is NOT listed on the FDA's official drug shortage database. So technically, there isn't a declared shortage. However, that doesn't mean it's always easy to find. Patients regularly report calling multiple pharmacies before locating a supply. Here's why.
5 Reasons Azstarys Can Be Hard to Find in 2026
1. It's a Brand-Only Medication With Low Routine Stocking
Pharmacies prioritize shelf space for medications they fill frequently. Because Azstarys has no generic equivalent and is a relatively newer medication (approved in 2021), many pharmacies simply don't stock it regularly. If your pharmacy doesn't receive many Azstarys prescriptions, it may not reorder it proactively — meaning it could be out of stock when you arrive, even if there's no formal shortage.
2. The Broader ADHD Stimulant Demand Surge Is Still Ongoing
The ADHD medication shortage that began with Adderall in October 2022 continues to create ripple effects across the entire stimulant medication category. More people are being diagnosed with ADHD than ever before — particularly adults. When popular medications like Adderall, Vyvanse, or Focalin XR are unavailable, patients are often switched to alternatives like Azstarys. That surge in demand can temporarily deplete pharmacies that don't stock large quantities.
3. DEA Production Quotas Apply to Dexmethylphenidate
As a Schedule II controlled substance, Azstarys is subject to DEA annual production quotas. The DEA did increase methylphenidate production quotas by approximately 9% in October 2025, which should improve supply over time — but the effects take months to reach pharmacy shelves. In the meantime, quota limits can constrain how much Azstarys can be manufactured in a given year.
4. Insurance Restrictions Can Drive Patients to Brand-Only Options
Some insurers require prior authorization or step therapy before they'll cover Azstarys. If a patient successfully navigates the approval process and gets coverage, they may specifically seek out Azstarys at pharmacies — but many pharmacies don't stock brand-only Schedule II medications in bulk. This mismatch between insurance coverage and pharmacy stocking patterns can make it harder to fill the prescription quickly.
5. Uneven Distribution Across Pharmacy Chains
Even when Azstarys is in stock in your region, it may not be evenly distributed across pharmacy chains. One CVS may have it while the one two miles away does not. Independent pharmacies often source through different wholesalers and may have different stock than major chains. This geographic patchwork makes it critical to check multiple locations.
How Hard Is It to Find Azstarys Compared to Other ADHD Medications?
Compared to generic Adderall or Focalin XR — which are frequently backordered — Azstarys is actually somewhat easier to find, partly because it's a newer brand-only medication with a smaller total number of prescriptions. Some pharmacists in ADHD-shortage-heavy areas have noted that Azstarys tends to be available at larger chain pharmacies even when other methylphenidate products are out. That said, availability can vary dramatically by ZIP code.
What Can You Do to Find Azstarys Near You?
Here are the most effective strategies for locating Azstarys in 2026:
Use medfinder: medfinder.com calls local pharmacies on your behalf to check which ones have Azstarys in stock and can fill your prescription. You provide your medication, dosage, and ZIP code — medfinder does the rest and texts you the results.
Call ahead and call often: Call multiple pharmacies — including independents — and ask specifically for the strength you need. Don't just check one chain.
Ask your prescriber about timing: Most pharmacies receive shipments at the start of the week. Filling your prescription on a Tuesday or Wednesday morning — right after a delivery — can improve your odds.
Try specialty or compounding pharmacies: Some specialty pharmacies maintain better stock of brand-only medications and may have Azstarys when chain pharmacies do not.
Talk to your doctor about alternatives: If Azstarys is consistently unavailable, your prescriber may be able to switch you to Focalin XR (dexmethylphenidate ER, available as a generic) as a therapeutic alternative. Read more in our guide on alternatives to Azstarys.
Will Azstarys Get Easier to Find?
The outlook is cautiously optimistic. The DEA's 2025 quota increases for methylphenidate should help ease supply across all methylphenidate-class medications, including the dexmethylphenidate component of Azstarys. However, no generic version of Azstarys is expected before 2037, so the brand-stocking challenge will likely persist until then.
For step-by-step instructions on finding Azstarys near you, see our guide: How to Find Dexmethylphenidate/Serdexmethylphenidate in Stock Near You.
Frequently Asked Questions
Azstarys is not listed on the FDA's official drug shortage database as of early 2026. However, it can still be intermittently difficult to find because it is a brand-only medication that many pharmacies do not routinely stock. The broader ADHD stimulant demand surge continues to affect availability.
Azstarys is a brand-only Schedule II stimulant with no generic alternative. Many pharmacies don't stock it routinely because prescription volume is lower than for older ADHD medications. The ongoing demand surge for all ADHD stimulants can also deplete whatever stock exists. Calling ahead or using medfinder to locate pharmacies with it in stock is your best approach.
Generally, yes. Azstarys tends to have somewhat better availability than generic Adderall or Focalin XR, partly because fewer total prescriptions are written for it. However, availability varies by region and pharmacy chain. Some areas may have the opposite experience.
No generic version of Azstarys (dexmethylphenidate/serdexmethylphenidate) is expected until at least 2037, based on current patent protections. Until then, patients will need to fill the brand-name product and manage the higher cost and variable availability that comes with brand-only medications.
The DEA sets annual production quotas for controlled substances including methylphenidate (the active metabolite of Azstarys). In October 2025, the DEA increased the methylphenidate quota by approximately 9%. This should improve supply for Azstarys and other methylphenidate-class medications over the course of 2026, though the effects take months to reach pharmacy shelves.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Dexmethylphenidate/Serdexmethylphenidate also looked for:
More about Dexmethylphenidate/Serdexmethylphenidate
29,999 have already found their meds with Medfinder.
Start your search today.





